Literature DB >> 3087663

Cardiovascular manifestations in Fabry's disease. A high incidence of mitral valve prolapse in hemizygotes and heterozygotes.

H Sakuraba, Y Yanagawa, T Igarashi, Y Suzuki, T Suzuki, K Watanabe, K Ieki, K Shimoda, T Yamanaka.   

Abstract

Cardiovascular manifestations of Fabry's disease were studied clinically in 10 hemizygous males and 13 heterozygous females. Mitral valve prolapse was found in 5 of 9 hemizygotes and in 5 of 13 heterozygotes examined by echocardiography. Ordinary medical examinations revealed cardiomyopathy in some asymptomatic females, and the diagnosis of the Fabry heterozygote was established by demonstration of specific inclusion bodies in the biopsied myocardium and low alpha-galactosidase activity in leukocytes. Renovascular hypertension of juvenile onset and thromboembolism were also found in 7 patients. It was concluded that Fabry's disease should always be considered in cases of mitral valve prolapse, cardiomyopathy, renovascular hypertension and thrombosis of unknown etiology, and that the Fabry patients should be followed carefully for the early detection of cardiovascular involvements in this disease.

Entities:  

Mesh:

Year:  1986        PMID: 3087663

Source DB:  PubMed          Journal:  Clin Genet        ISSN: 0009-9163            Impact factor:   4.438


  7 in total

1.  Fabry disease: correlation between structural changes in alpha-galactosidase, and clinical and biochemical phenotypes.

Authors:  Fumiko Matsuzawa; Sei-ichi Aikawa; Hirofumi Doi; Toshika Okumiya; Hitoshi Sakuraba
Journal:  Hum Genet       Date:  2005-05-28       Impact factor: 4.132

Review 2.  Cardiac manifestations in Fabry disease.

Authors:  A Linhart; J C Lubanda; T Palecek; J Bultas; D Karetová; J Ledvinová; M Elleder; M Aschermann
Journal:  J Inherit Metab Dis       Date:  2001       Impact factor: 4.982

3.  FABRY'S DISEASE: A Case Report.

Authors:  Abha K Sabhikhi; P P Verma; P S Reddy; H Kumar; Ramji Rai
Journal:  Med J Armed Forces India       Date:  2017-06-26

4.  Cardiocyte storage and hypertrophy as a sole manifestation of Fabry's disease. Report on a case simulating hypertrophic non-obstructive cardiomyopathy.

Authors:  M Elleder; V Bradová; F Smíd; M Budĕsínský; K Harzer; B Kustermann-Kuhn; J Ledvinová; V Král; V Dorazilová
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1990

5.  Corrective effect on Fabry mice of yeast recombinant human alpha-galactosidase with N-linked sugar chains suitable for lysosomal delivery.

Authors:  Hitoshi Sakuraba; Yasunori Chiba; Masaharu Kotani; Ikuo Kawashima; Mai Ohsawa; Youichi Tajima; Yuki Takaoka; Yoshifumi Jigami; Hiroshi Takahashi; Yukihiko Hirai; Takashi Shimada; Yasuhiro Hashimoto; Kumiko Ishii; Toshihide Kobayashi; Kazuhiko Watabe; Tomoko Fukushige; Tamotsu Kanzaki
Journal:  J Hum Genet       Date:  2006-03-11       Impact factor: 3.172

6.  Fabry's disease with complete atrioventricular block: histological evidence of involvement of the conduction system.

Authors:  Y Ikari; K Kuwako; T Yamaguchi
Journal:  Br Heart J       Date:  1992-09

Review 7.  Fabry Disease and the Heart: A Comprehensive Review.

Authors:  Olga Azevedo; Filipa Cordeiro; Miguel Fernandes Gago; Gabriel Miltenberger-Miltenyi; Catarina Ferreira; Nuno Sousa; Damião Cunha
Journal:  Int J Mol Sci       Date:  2021-04-23       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.